Natera Business Summary

Natera, Inc. (NTRA) is a global leader in cell-free DNA (cfDNA) testing, generating revenue primarily through a high-volume diagnostic service model supported by third-party payer reimbursements and biopharmaceutical partnerships. The company’s business is structured into three high-growth segments: Oncology, anchored by its market-leading Signatera molecular residual disease (MRD) test; Women’s Health, featuring the Panorama non-invasive prenatal test (NIPT) and Horizon carrier screening; and Organ Health, centered on the Prospera transplant rejection assessment platform. As of early 2026, Natera has solidified its position as a precision medicine powerhouse, reporting full-year 2025 revenues of approximately $2.3 billion, a 35% increase over the prior year driven by record adoption of its oncology portfolio. In the competitive landscape, Natera competes directly with Guardant Health in the MRD space, Exact Sciences in cancer screening, and CareDx in transplant diagnostics. Natera maintains a dominant market position through its proprietary "tumor-informed" personalized approach, which provides significantly higher sensitivity for early cancer recurrence detection compared to the tumor-agnostic liquid biopsy methods utilized by many of its peers. The company was co-founded by Dr. Matthew Rabinowitz, who serves as Executive Chairman and holds a Ph.D. from Stanford University, and Jonathan Sheena, a co-founder and director. The executive leadership team is headed by CEO Steve Chapman, who has been instrumental in Natera’s commercial scaling and its strategic pivot into the oncology market. Key management includes Chief Financial Officer Mike Brophy, a former Morgan Stanley investment banker, and John Fesko, who serves as President and Chief Business Officer. Clinical and technical strategy is led by Dr. Alexey Aleshin, General Manager of Oncology and Chief Medical Officer. Natera’s board of directors includes prominent industry figures such as Roelof Botha, Managing Partner at Sequoia Capital, and Dr. Roy Baynes, former Chief Medical Officer at Merck. The company is backed by a robust institutional investor base, including major stakeholders like Baillie Gifford and Vanguard, reflecting sustained confidence in Natera’s long-term roadmap for personalized genomic diagnostics.